Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I
- PMID: 30954369
- DOI: 10.1016/j.ymgme.2019.01.019
Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I
Abstract
Hereditary tyrosinemia type 1 (HT1), the most severe disease of the tyrosine catabolic pathway, is caused by a deficiency of fumarylacetoacetate hydrolase (FAH). More than 90 disease-causing variants have been identified in the fah gene. We investigated the molecular defect in a patient who presented atypical symptoms for the disease. No immunoreactive FAH was found in the liver and RNA analysis by RT-PCR suggested the presence of splicing mutations. Indeed, the patient was revealed to be a compound heterozygote for IVS6-1 g- > t and two new variants, namely p.V259L and p.G398E. Using splicing minigene constructs transfected in HeLa cells, the c.775G > C variant (p.V259L) was shown to affect partially exon 9 splicing thereby allowing the production of some full-length double-mutant FAH transcripts. The p.G398E variant had a major impact on enzyme activity, which was worsened by the p.V259L variant. Surprisingly, the double mutant protein was expressed to similar level as the wild-type protein upon transfection in HeLa cells but was absent in the patient liver extract, suggesting a higher propensity to be degraded in the hepatocellular context.
Copyright © 2019. Published by Elsevier Inc.
Similar articles
-
A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.BMC Genet. 2001;2:9. doi: 10.1186/1471-2156-2-9. Epub 2001 Jun 29. BMC Genet. 2001. PMID: 11476670 Free PMC article.
-
Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):641-5. doi: 10.1073/pnas.98.2.641. Proc Natl Acad Sci U S A. 2001. PMID: 11209059 Free PMC article.
-
Molecular Aspects of the FAH Mutations Involved in HT1 Disease.Adv Exp Med Biol. 2017;959:25-48. doi: 10.1007/978-3-319-55780-9_3. Adv Exp Med Biol. 2017. PMID: 28755182 Review.
-
Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant.Mol Genet Genomic Med. 2019 Dec;7(12):e937. doi: 10.1002/mgg3.937. Epub 2019 Sep 30. Mol Genet Genomic Med. 2019. PMID: 31568711 Free PMC article.
-
Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.Adv Exp Med Biol. 2017;959:9-21. doi: 10.1007/978-3-319-55780-9_2. Adv Exp Med Biol. 2017. PMID: 28755181 Review.
Cited by
-
Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: Consensus group recommendations from the German-speaking countries.J Inherit Metab Dis. 2025 Jan;48(1):e12824. doi: 10.1002/jimd.12824. J Inherit Metab Dis. 2025. PMID: 39676394 Free PMC article. Review.
-
The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1).Mol Genet Genomic Med. 2023 Jan;11(1):e2090. doi: 10.1002/mgg3.2090. Epub 2022 Nov 12. Mol Genet Genomic Med. 2023. PMID: 36369907 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous